NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP today announced that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, in an upsized underwritten public offering. The offering, including the full exercise of the overallotment, consisted of 10,147,059 shares of common stock at a price to the public of $17.00 per share. The gross proceeds of the offering to the company were approximately $172.5 million.
Relmada intends to use the net proceeds to fund research and development activities for its clinical development programs related to Relmada’s lead product candidate, REL-1017 (esmethadone), which is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications, as well as for working capital and general corporate purposes.
Sichenzia Ross Ference LLP also represented RLMD in its $115 million underwritten public offering of common stock in December 2019. SRF is looking forward to this continued partnership and supporting this important research and the great team at Relmada.
Goldman Sachs & Co. LLC, Jefferies and Guggenheim Securities acted as the joint book-running managers for the offering.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Barrett DiPaolo, and associates Matthew Siracusa and Ryan Flynn.
About Sichenzia Ross Ference LLP
SRF is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRF’s renowned litigation department specializes in defending companies and individuals against all types of securities cases, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations. The litigation team has also brought defamation lawsuits against companies and individuals related to market manipulation.
The firm also represents individuals and companies in investigations by the Securities and Exchange Commission (SEC) and other regulatory bodies. The litigation team has a robust practice representing brokers and broker-dealers in arbitrations before the Financial Industry Regulatory Authority (FINRA). These arbitrations typically involve claims of unsuitability, churning, unauthorized trading and other allegations of broker misconduct. Finally, SRF has a burgeoning expungement practice, where it represents brokers seeking to have negative and harmful customer complaints removed from their industry records. The firm complements its core practice areas with an established commercial real estate and trusts and estates practice.
